ALUMIS INC
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ALMS$6.40-2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| | Three Months Ended March 31, | |||||
| (in thousands) · · 2025 · 2024 | ||||||
| Cash flows from operating activities · · | ||||||
| Net loss | | $(98,963) | | $(49,849) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 6,995 | | 2,657 | ||
| Change in fair value of derivative liability | | — | | 3,095 | ||
| Net accretion of discounts on marketable securities | | (983) | | (48) | ||
| Depreciation and amortization | | 843 | | 758 | ||
| Non-cash lease expense | | 266 | | 11 | ||
| Changes in operating assets and liabilities: | | | | | ||
| Research and development prepaid expenses | | 561 | | (2,949) | ||
| Other prepaid expenses and other assets | | 583 | | (165) | ||
| Other long term assets | | | (38) | | | — |
| Accounts payable | | (2,151) | | 5,715 | ||
| Deferred revenue | | | 2,611 | | | — |
| Research and development accrued expenses | | 5,550 | | 229 | ||
| Other accrued expenses and current liabilities | | 4,988 | | (3,212) | ||
| Operating lease liabilities | | (617) | | (504) | ||
| Net cash used in operating activities | | (80,355) | | (44,262) | ||
| Cash flows from investing activities | | | ||||
| Maturities of marketable securities | | 64,000 | | 1,000 | ||
| Purchases of marketable securities | | (24,535) | | (19,655) | ||
| Purchases of property and equipment | | (37) | | (155) | ||
| Net cash provided by (used in) investing activities | | 39,428 | | (18,810) | ||
| Cash flows from financing activities | | | ||||
| Proceeds from issuance of redeemable convertible preferred stock and derivative liability, net of issuance costs | | — | | 129,118 | ||
| Proceeds from issuance of common stock upon exercise of stock options | | — | | 29 | ||
| Net cash provided by financing activities | | — | | 129,147 | ||
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (40,927) | | 66,075 | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 170,632 | | 47,133 | ||
| Cash, cash equivalents and restricted cash at end of period | | $129,705 | | $113,208 | ||
| Supplemental disclosures: | | | ||||
| Recognition of derivative liability upon issuance of redeemable convertible preferred stock | | $— | | $8,913 | ||
| Vesting of early exercised stock options and unvested restricted shares of common stock | | $226 | | $500 | ||
| Deferred offering costs in accounts payable and other accrued expenses and current liabilities | | $— | | $235 | ||
| Right-of-use assets obtained in exchange for operating lease liabilities | | $1,776 | | $— | ||
| Purchases of property and equipment in other accrued expenses and current liabilities | | $165 | | $301 | ||
| Reconciliation of cash, cash equivalents and restricted cash: | | | | |||
| Cash and cash equivalents | | $128,543 | | $112,071 | ||
| Restricted cash | | — | | 113 | ||
| Restricted cash, non-current | | 1,162 | | 1,024 | ||
| Total cash, cash equivalents and restricted cash | | $129,705 | | $113,208 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.